Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NK

NantKwest (NK) Stock Price, News & Analysis

NantKwest logo

About NantKwest Stock (NASDAQ:NK)

Key Stats

Today's Range
$4.81
$5.05
50-Day Range
$16.09
$38.70
52-Week Range
$2.52
$45.42
Volume
4.15 million shs
Average Volume
1.57 million shs
Market Capitalization
$528.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive NK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

NK Stock News Headlines

Space Nk Promo Codes
Election warning coming true…
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
NantKwest Inc (IBRX) Earnings Dates & Reports
See More Headlines

NK Stock Analysis - Frequently Asked Questions

NantKwest, Inc. (NASDAQ:NK) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. NantKwest had a negative net margin of 76,658.58% and a negative trailing twelve-month return on equity of 56.06%.

NantKwest (NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Dynavax Technologies (DVAX) and OPKO Health (OPK).

Company Calendar

Last Earnings
5/11/2020
Today
11/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Net Income
$-65,790,000.00
Net Margins
-76,658.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Price / Sales
13,203.41
Book Value
$1.23 per share

Miscellaneous

Free Float
N/A
Market Cap
$528.14 million
Optionable
Not Optionable
Beta
2.61
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:NK) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners